(2S,4S,5S,7S)-7-(3-(3-Methoxypropoxy)-4-methoxybenzyl)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide hydrochloride manufacturers
|
| | (2S,4S,5S,7S)-7-(3-(3-Methoxypropoxy)-4-methoxybenzyl)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide hydrochloride Basic information |
| Product Name: | (2S,4S,5S,7S)-7-(3-(3-Methoxypropoxy)-4-methoxybenzyl)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide hydrochloride | | Synonyms: | (2S,4S,5S,7S)-7-(3-(3-Methoxypropoxy)-4-methoxybenzyl)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide hydrochloride;(αS,γS,δS,zS)-δ-AMino-N-(3-aMino-2,2-diMethyl-3-oxopropyl)-γ-hydroxy-4-Methoxy-3-(3-Methoxypropoxy)-α,z-bis(1-Methylethyl)benzeneoctanaMide Hydrochloride;Rasilez Hydrochloride;Tekturna Hydrochloride;Aliskiren Hydrochloride;(2S,4S,5S,7S)-5-AMino-N-(3-aMino-2,2-diMethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-Methoxy-3-(3-Methoxypropoxy)benzyl)-8-MethylnonanaMide hydrochloride;Aliskiren HCl | | CAS: | 173399-03-6 | | MF: | C30H54ClN3O6 | | MW: | 588.23 | | EINECS: | | | Product Categories: | Pharmaceuticals;Intermediates & Fine Chemicals;Chiral Reagents;Amines | | Mol File: | 173399-03-6.mol |  |
| | (2S,4S,5S,7S)-7-(3-(3-Methoxypropoxy)-4-methoxybenzyl)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide hydrochloride Chemical Properties |
| Melting point | 76-78°C | | storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere | | solubility | Chloroform, Methanol | | form | Solid | | color | White to Pale Yellow | | Stability: | Hygroscopic |
| | (2S,4S,5S,7S)-7-(3-(3-Methoxypropoxy)-4-methoxybenzyl)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide hydrochloride Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Uses | An orally active, synthetic nonpeptide renin inhibitor. Antihypertensive. | | in vivo | Aliskiren hydrochloride (3 mg/kg, 10 mg/kg; p.o.; daily; 0-12 d) inhibit renin and lower blood pressure without affecting heart rate in sodium-depleted marmosets[3].
Aliskiren hydrochloride (10 mg/kg; p.o.; single dose) delays cachexia development, reduces tumor, and prolongs mouse survival. And also improves whole body strength, mobility and coordination, enhances locomotor activity, and inhibits muscle wasting[4].
Aliskiren hydrochloride (10 mg/kg; p.o.; single dose; 20 d after C26 injection) reduces oxidative stress associated with cancer cachexia[4].
| Animal Model: | Sodium-depleted marmosets[3] | | Dosage: | 3 mg/kg, 10 mg/kg | | Administration: | Oral gavage; once daily; 12 days | | Result: | Increased plasma immunoreactive renin levels, and lowered blood pressure without affecting heart rate.
Showed no rebound increase in BP following the end of treatment with either dose of aliskiren.
Inhibited the RAS and controls the upregulation of proinflammatory cytokines.
|
| Animal Model: | Cancer cachexia model in BALB/c mice injected with C26 mouse colon carcinoma cells[4] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; on day 5 (as a preventive strategy, AP group) or on day 12 (as a therapeutic strategy, AT group) after C26 injection; for 20 days after C26 injection | | Result: | Enhanced grip strength, coordination, and locomotor activity.
Inhibited serum Ang I and Ⅱ levels and both serum and muscular tumor necrosis factorα (TNFα) and inter leukin6 (IL6) levels.
|
|
| | (2S,4S,5S,7S)-7-(3-(3-Methoxypropoxy)-4-methoxybenzyl)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide hydrochloride Preparation Products And Raw materials |
|